BioSpace News Archive

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced positive topline results from its randomized, dose ranging, placebo controlled, pivotal Phase 2/3 clinical trial (BHV3500-201; NCT03872453) evaluating the efficacy and tolerability of intranasal vazegepant 5, 10 and 20 mg versus placebo in 1,673 patients for the acute treatment of migraine.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 16,125,000 common shares (the “Offering”) at a price of US$4.00 per share. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aptose, are expected to be approximately US$64.5 million.

TRHC’s SinfoniaRx® Clinical Intelligence Call Centers to provide comprehensive medication reviews to improve medication adherence and optimize care

The Honourable Patty Hajdu, Minister of Health, issued the following statement on new cannabis products entering the legal and regulated market

ArcherDX, Inc., today announced the close of a $55 million Series C financing round led by Perceptive Advisors, which was joined by new investors Redmile Group, Soleus Capital, Driehaus Capital Management and ArrowMark Partners, as well as existing investors Sands Capital, Longwood Fund, PBM Capital and its affiliates, Boulder Ventures and others.

Study evaluates the differences in sensitivity of ovarian cancer risk detection between OVA1® Plus and CA125

Mr. Heffernan was most recently CEO of Collegium Pharmaceutical, a publicly traded pharmaceutical company that he founded and that is focused on developing and commercializing products for the treatment of chronic pain and related disorders.

Expanded market access expertise strengthens Alira Health’s suite of healthcare advisory services.

Ergonomic baby carrier Mamapod is honored to partner with The International Hip Dysplasia Institute (IHDI) as part of a corporate social responsibility program titled, the “Research Partnership Program.

A premier biopharmaceutical company, this client provides high quality, life-saving and affordable biotherapeutics to patients across the world.